Literature DB >> 23798010

Congenital disorders of glycosylation and intellectual disability.

Lynne A Wolfe1, Donna Krasnewich.   

Abstract

The congenital disorders of glycosylation (CDG) are a rapidly growing group of inborn errors of metabolism that result from defects in the synthesis of glycans. Glycosylation is a major post-translational protein modification and an estimated 2% of the human genome encodes proteins for glycosylation. The molecular bases for the current 60 disorders, affecting approximately 800 individuals, have been identified, many in the last 5 years. CDG should be considered in any multi-system syndrome or single tissue disorder not explained by the identification of another disorder. The initial clinical presentation varies significantly among individuals, even between affected siblings. However, two thirds of the known CDGs are associated with intellectual disabilities and most affected individuals need support services throughout their lives. Additional disorders of glycosylation are likely to be characterized over time.
Copyright © 2013 Wiley Periodicals, Inc., a Wiley company.

Entities:  

Mesh:

Year:  2013        PMID: 23798010     DOI: 10.1002/ddrr.1115

Source DB:  PubMed          Journal:  Dev Disabil Res Rev        ISSN: 1940-5529


  7 in total

1.  An Unexplained Congenital Disorder of Glycosylation-II in a Child with Neurohepatic Involvement, Hypercholesterolemia and Hypoceruloplasminemia.

Authors:  Pier Luigi Calvo; Marco Spada; Ivana Rabbone; Michele Pinon; Francesco Porta; Fabio Cisarò; Stefania Reggiani; Angelo B Cefalù; Luisella Sturiale; Domenico Garozzo; Dirk J Lefeber; Jaak Jaeken
Journal:  JIMD Rep       Date:  2017-06-23

2.  Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment.

Authors:  Yu Zhang; Xiaomin Yu; Mie Ichikawa; Jonathan J Lyons; Shrimati Datta; Ian T Lamborn; Huie Jing; Emily S Kim; Matthew Biancalana; Lynne A Wolfe; Thomas DiMaggio; Helen F Matthews; Sarah M Kranick; Kelly D Stone; Steven M Holland; Daniel S Reich; Jason D Hughes; Huseyin Mehmet; Joshua McElwee; Alexandra F Freeman; Hudson H Freeze; Helen C Su; Joshua D Milner
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

Review 3.  The role of post-translational modifications in hearing and deafness.

Authors:  Susana Mateo Sánchez; Stephen D Freeman; Laurence Delacroix; Brigitte Malgrange
Journal:  Cell Mol Life Sci       Date:  2016-05-04       Impact factor: 9.261

4.  Mitotic Intragenic Recombination: A Mechanism of Survival for Several Congenital Disorders of Glycosylation.

Authors:  Megan S Kane; Mariska Davids; Christopher Adams; Lynne A Wolfe; Helen W Cheung; Andrea Gropman; Yan Huang; Bobby G Ng; Hudson H Freeze; David R Adams; William A Gahl; Cornelius F Boerkoel
Journal:  Am J Hum Genet       Date:  2016-01-21       Impact factor: 11.025

5.  Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) gene.

Authors:  Karin E Lundin; Abdulrahman Hamasy; Paul Hoff Backe; Lotte N Moens; Elin Falk-Sörqvist; Katja B Elgstøen; Lars Mørkrid; Magnar Bjørås; Carl Granert; Anna-Carin Norlin; Mats Nilsson; Birger Christensson; Stephan Stenmark; C I Edvard Smith
Journal:  Clin Immunol       Date:  2015-10-19       Impact factor: 3.969

6.  DPAGT1-CDG: Functional analysis of disease-causing pathogenic mutations and role of endoplasmic reticulum stress.

Authors:  Patricia Yuste-Checa; Ana I Vega; Cristina Martín-Higueras; Celia Medrano; Alejandra Gámez; Lourdes R Desviat; Magdalena Ugarte; Celia Pérez-Cerdá; Belén Pérez
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

Review 7.  Clinical diagnostics and therapy monitoring in the congenital disorders of glycosylation.

Authors:  Monique Van Scherpenzeel; Esther Willems; Dirk J Lefeber
Journal:  Glycoconj J       Date:  2016-01-07       Impact factor: 2.916

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.